Web Results

Alemtuzumab - Wikipedia

en.wikipedia.org/wiki/Alemtuzumab

Alemtuzumab is a drug used in the treatment of chronic lymphocytic leukemia ( CLL), cutaneous T-cell lymphoma (CTCL) and T-cell lymphoma under the trade ...

Campath.com Consumer Home

www.campath.com/

Campath, alemtuzumab is a major step forward in the treatment of B-cell chronic lymphocytic leukemia (B-CLL).

Relapsing MS Infusion Treatment | LEMTRADA® (alemtuzumab)

www.lemtrada.com/

LEMTRADA®, because of its risks, is generally for relapsing MS patients who have tried 2 or more MS medicines that didn't work well enough.

Campath (Alemtuzumab): Side Effects, Interactions, Warning ... - RxList

www.rxlist.com/campath-drug.htm

Learn about Campath (Alemtuzumab) may treat, uses, dosage, side effects, drug interactions, warnings, patient labeling, reviews, and related medications.

Campath, Lemtrada (alemtuzumab) dosing, indications, interactions ...

reference.medscape.com/drug/campath-lemtrada-alemtuzumab-342240

Medscape - Chronic lymphocytic leukemia and multiple sclerosis dosing for Campath, Lemtrada (alemtuzumab), frequency-based adverse effects, ...

alemtuzumab intravenous : Uses, Side Effects, Interactions, Pictures ...

www.webmd.com/drugs/2/drug-21057/alemtuzumab-intravenous/details

Find patient medical information for alemtuzumab intravenous on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ...

Alemtuzumab - Drug Information - Chemocare

chemocare.com/chemotherapy/drug-info/alemtuzumab.aspx

(ay-lem-TOO-zuh- mab). Trade name: Campath<sup>®</sup>. Chemocare.com uses generic names in all descriptions of drugs. Campath is the trade name for alemtuzumab ...

Alemtuzumab (MabCampath) | Cancer Research UK

www.cancerresearchuk.org/about-cancer/cancers-in-general/treatment/cancer-drugs/alemtuzumab

Dec 17, 2015 ... The biological therapy drug alemtuzumab is a treatment for chronic lymphocytic leukaemia. The possible side effects inlcude an increased risk ...

Alemtuzumab therapy for multiple sclerosis. - NCBI

www.ncbi.nlm.nih.gov/pubmed/23184314

Alemtuzumab is a humanized monoclonal antibody that is administered daily for 5 days, and then no further therapy is required for 12 months. It causes rapid ...

FDA Approves Lemtrada™ (alemtuzumab) for Relapsing MS ...

www.nationalmssociety.org/About-the-Society/News/FDA-Approves-Lemtrada™-(alemtuzumab)-for-Relapsing

Nov 14, 2014 ... UPDATED December 18, 2014. The U.S. Food and Drug Administration has approved Lemtrada™ (alemtuzumab, Genzyme, a Sanofi ...